BEP regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
[[Cisplatin|{{button|P – Cisplatin (Platinol)}}]] | [[Cisplatin|{{button|P – Cisplatin (Platinol)}}]] | ||
==Indications== | ==Indications== | ||
* [[Ovarian germ-cell tumors| | * [[Ovarian germ-cell tumors|Advanced-stage ovarian germ-cell tumors]]<ref name="pmid25559616">{{cite journal| author=Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y et al.| title=Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. | journal=Eur J Cancer | year= 2015 | volume= 51 | issue= 3 | pages= 340-51 | pmid=25559616 | doi=10.1016/j.ejca.2014.12.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25559616 }} </ref> | ||
* [[Testicular germ-cell tumors| | * [[Testicular germ-cell tumors|Advanced-stage testicular germ-cell tumors]]<ref name="pmid25559616">{{cite journal| author=Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y et al.| title=Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. | journal=Eur J Cancer | year= 2015 | volume= 51 | issue= 3 | pages= 340-51 | pmid=25559616 | doi=10.1016/j.ejca.2014.12.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25559616 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] |
Revision as of 16:34, 27 February 2015
WikiDoc Resources for BEP regimen |
Articles |
---|
Most recent articles on BEP regimen Most cited articles on BEP regimen |
Media |
Powerpoint slides on BEP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on BEP regimen at Clinical Trials.gov Clinical Trials on BEP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on BEP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on BEP regimen Discussion groups on BEP regimen Patient Handouts on BEP regimen Directions to Hospitals Treating BEP regimen Risk calculators and risk factors for BEP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for BEP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BEP; BEP Regimen; BEP regimen; Bleomycin-Etoposide-Platinol Regimen; PEB Regimen; Platinol-Etoposide-Bleomycin Regimen
Overview
BEP regimen refers to a regimen consisting of bleomycin, etoposide and cisplatin(Platinol) used to treat advanced-stage ovarian and testicular germ-cell tumors.[1][2]
Regimen
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ 3.0 3.1 Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y; et al. (2015). "Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour". Eur J Cancer. 51 (3): 340–51. doi:10.1016/j.ejca.2014.12.004. PMID 25559616.